• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Biotricity Awarded Ethics Approval to Validate Mobile Wireless Fetal Monitoring

by Jasmine Pennic 06/20/2017 Leave a Comment

AT&T Taps biotricity To Power Wearable Medical Devices Medical

Biotricity, Inc., a provider of biometric remote monitoring solutions has been awarded ethics approval to conduct a study that will investigate and validate a mobile wireless fetal heart rate variability (HRV) monitor. Conducted at Rockyview General Hospital, the findings of the study will be used to build on the research of Biotricity’s flagship product Bioflux which is currently awaiting final FDA clearance and will be the second major app for the clinical-grade remote patient monitoring device.

Study Overview

Early and consistent prenatal care improves the chances of a healthy pregnancy for both mother and child. Prenatal monitoring helps physicians and other caregivers to better control existing conditions in the mother, such as high blood pressure and diabetes, and help avoid serious complications in pregnancy from other disorders, such as preeclampsia. Regular monitoring reduces the infant’s risk for complications as well, making unforeseeable risks more predictable, manageable and potentially preventable.

Mobile, wearable systems for fetal ECG recording will allow for real-time and real-life evaluation of both the baby’s and mother’s status. An electrical sensing ECG monitor provides a higher sampling rate than conventional techniques. This allows for a higher level of heart rate variability processing and automation, which can help differentiate artifacts from the heart rates of both the mother and the baby. This enhanced accuracy could further help save lives and improve the overall quality of prenatal care.

“Estimating the heart rate variability pre-birth is a natural progression for Biotricity, whose main goal in this sphere is to research future medical devices that are easy to implement in both the physician’s office and the patient’s home, that are comfortable and small, and that can offer precise remote data and care,” said Waqaas Al-Siddiq, Founder and CEO of Biotricity. “We are extremely excited to receive ethics approval and look forward to building on the research of our flagship product, Bioflux, which is a highly accurate, clinical-grade remote patient monitoring device that specifically focuses on individuals diagnosed with or at risk for cardiovascular disease.”

Tagged With: biotricity, Clinical-Grade Wearable, wireless fetal/maternal monitoring

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved

Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved

GE HealthCare to Acquire Caption Health

GE HealthCare to Acquire Caption Health to Expand AI-Guided Ultrasounds

Epic, Impact Advisors, Nordic, Chartis Named 2023 Overall Best in KLAS® Awards

Epic, Impact Advisors, Nordic, Chartis Named 2023 Overall Best in KLAS® Awards

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |